Find a Treatment Center

Investor Relations

Contact Us

KiteKonnect®

About Us
Our Mission Our Story Therapeutic Areas Leadership Kite Locations
Science & Medicine
Our Technology Our Therapies Pipeline Trials & Expanded Access External Research Program (ERP)
Newsroom
Newsroom Press Releases Company Statements Media Kit
Careers
Now Hiring Careers at Kite Manufacturing Careers at Kite Early Talent Programs at Kite Culture & Benefits
Utility
Contact Us KiteKonnect®

BACK TO MAIN MENU Company Statements Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma Kite Announces U.S. FDA Clearance of Investigational

Find a Treatment Center
Investor Relations

Toggle Inner Dropdown

BACK TO MAIN MENU Google.com

Media Kit

View our media materials:

Non-Hodgkin Lymphoma

Understanding Chimeric Antigen Receptor (CAR) T Cell Technology

AREAS OF INTEREST

Our Mission
Our Technology
Pipeline
Careers at Kite

INFORMATION

Contact Us
Newsroom
Investors
KiteKonnect.com
Gilead.com
Sitemap

LEGAL

Privacy Policy
Terms and Conditions
Compliance Program
Social Media Guidelines

FOLLOW US

© 2017-2022 Gilead Sciences, Inc. All rights reserved.

For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483)